Glaukos (NYSE:GKOS) announced today that it entered into a settlement with Ivantis to terminate a three-year-old patent infringement lawsuit. San Clemente, California-based Glaukos’ patent infringement lawsuit, initiated on April 14, 2018, in the U.S. District Court for the Central District of California, Southern Division, concerned Ivantis’ Hydrus Microstent for reducing eye pressure in glaucoma patients. Get the full […]
Ivantis
Glaukos touts 5-year study of glaucoma stents
Glaukos (NYSE:GKOS) said today that a study of its iStent trabecular micro-bypass stents reduced eye pressure in glaucoma patients five years after implant. The same study showed that significantly fewer iStent patients needed add-on medications after five years, the company said. The study showed that newly diagnosed, primary open-angle glaucoma (POAG) patients who received two […]
Ivantis touts 2-year Hydrus, Glaukos iStent head-to-head study results
Ivantis today released two-year results from a study comparing its Hydrus Microstent to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting reductions in medication use and no reoperations for patients in the Hydrus arm. The Irvine, Calif.-based company said that it is presenting results from the Compare trial today at the American Glaucoma Society’s annual meeting in […]
New eye health companies gain funders’ focus
Startups pioneering less-invasive technologies to treat common eye diseases are changing the outlook for both patients and the industry. A new study by CB Insights revealed that investors have been pouring money into smaller companies in 2017 and 2018, with some FDA approvals to begin marketing their technologies and treatments. These firms are eyeing conditions […]
FDA approves Ivantis’ Hydrus microstent
Ivantis said today it won FDA approval for its Hydrus microstent designed to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The Hydrus microstent is designed for minimally invasive microsurgical procedures to reduce eye pressure in patients with glaucoma. The device is multi-modal, the company said, by creating a large […]
Ivantis touts 1-year head-to-head Hydrus, Glaukos iStent study data
Ivantis today released one-year results from the study of its Hydrus Microstent comparing it to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting the Hydrus’ ability to reduce reliance on medication and intraocular pressure. Results from the trial were presented at the American Society of Cataract and Refractive Surgery annual meeting in Washington D.C. by Dr. David […]
Ivantis launches 2nd IDE study of Hydrus microstent
Ivantis said today it won approval from the FDA to initiate a 2nd investigational device exemption trial of its Hydrus microstent, testing the device in patients with advanced glaucoma who are undergoing stand-alone glaucoma surgery without combined cataract surgery. The Hydrus microstent is designed for minimally invasive microsurgical procedures to reduce eye pressure in patients with […]
Ivantis raises $25m in Series C to support Hydrus microstent
Ivantis said today it raised $25 million in a Series C round of financing to support its Hydrus microstent device designed for treating glaucoma. The round was led by newly invested RA Capital Management and joined by new investor Mérieux Développement and existing investors. Money raised will extend Irvine, Calif.-based Ivantis’ runway into 2020 and […]
Silicon Valley Bank’s Ben Johnson talks early-stage medtech investment slump | Medtech funding for the week of September 22, 2014
Ivantis adds $25M, eyes U.S. approval for glaucoma micro-stent
Ivantis today said it added a $25 million tranche to its now $71 million Series B round as the Irvine, Calif.-based company looks to bring its miniature glaucoma scaffold to the U.S. market.
Ivantis rakes in $46.5M and advances U.S. trial for glaucoma device
Opthalmic devices maker Ivantis padded its Series B funding round with another $14 million raised, bringing the total to $46.5 million.
The funds are slated to help Ivantis through 3 large clinical trials and may be enough to get the company through U.S. approval for its Hydrus Microstent glaucoma treatment device.
